Meanwhile, on The Bull this week, Dylan Evans from Catapult Wealth explains his views on three ASX 200 shares.

Let's check them out. 

Transurban Group (ASX: TCL)

The Transurban share price is $14.93, down 0.8% today and down 1% over six months.

Evans has a buy rating on this ASX 200 industrials share, and explains:  

TCL operates toll roads in Australia and the United States. It generates reliable inflation linked cash flows, underpinning a relatively defensive stock.

The shares are sensitive to rising interest rates, partially due to its significant debt, which, in our view, has weighed on the stock in the past few years.

During the same time, Transurban has been growing traffic volumes and has been involved in completing several significant projects, including the West Gate Tunnel in Melbourne.

Any easing in inflation and interest rates would boost the company's performance.

In the meantime, Transurban offers an attractive dividend yield, reliable earnings and a development pipeline with long term growth potential.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price is $18.96, up 0.9% on Thursday and down 18% over six months.

Evans has a hold rating on this ASX 200 healthcare share, and says:

Sonic is a leading global provider of clinical laboratory services, including pathology and radiology. The company increased revenue by 17 per cent in the first half of 2026 when compared to the prior corresponding period. Net profit after tax was up 10 per cent.

The company is on track to achieve full year EBITDA guidance of between $1.87 billion to $1.95 billion on a constant currency basis.

If positive momentum continues, Sonic looks like a solid value play. Sonic was recently trading on a modest price/earnings multiple of about 17 times and a partially franked dividend yield of about 5.7 per cent.

An ageing population underpins demand for laboratory services, so SHL should be able to grow at high double digits over the long term.

A2 Milk Company Ltd (ASX: A2M)

The A2 Milk share price is $5.29, down 1.1% today and 44% over the past six months.

Evans has a sell rating on this ASX 200 consumer staples share, commenting:  

This infant milk formula company recently initiated a voluntary recall of three small batches of contaminated product sold only in the United States.

While the recall didn't impact the key Chinese market, it poses a reputational risk in a country and segment that is sensitive to brand reputation.

A recent trading update revealed supply chain disruptions are constraining product availability despite strong underlying demand.

The shares have remained under pressure since April when the company downgraded guidance in full year 2026.

The post Buy, hold, sell: Transurban, Sonic Healthcare, A2 Milk shares appeared first on The Motley Fool Australia.

When markets are volatile, it's important to know which ASX 200 shares are good investments and which have a weaker outlook.

Here are 5 ASX 200 shares that brokers rate as a sell, according to Market Index data.

Westpac Banking Corp (ASX: WBC)

Westpac shares are down around 2% at the time of writing to $35.44 each. The banking giant's shares are now around 9% lower year to date but still 10% higher than 12 months ago. The bank posted a solid first-half result in early May, but broad bank sector weakness has still pulled the shares lower. Westpac shares came under additional selling pressure last month after a court ruling weighed on sentiment. It looks like Westpac shares could still be overvalued. The majority of brokers rate Westpac shares as a strong sell and tip a 4% downside to an average target price of $33.97 over the next 12 months.

Sonic Healthcare Ltd (ASX: SHL)

Sonic shares hit a multi-year low in late May and have continued to regain any meaningful momentum. At the time of writing, the shares are down around another 2.5% to $18.78 each. For the year to date, the ASX 200 healthcare shares are down around 16% and are 30% lower than this time last year. Sonic has been caught up in the sector-wide rotation away from ASX healthcare shares this year, and it has also faced some company-specific headwinds. The team at Ord Minnett thinks the company could be negatively affected by proposed changes to medical fees in Germany and notes that it lacks organic growth. Market Index data shows a combined sell rating. But after last month's sell-off, the average target price still implies a potential 13% upside, at the time of writing.

Bank of Queensland Ltd (ASX: BOQ)

The mid-tier ASX 200 bank's share is down around 1% at the time of writing, to $6.13 a piece. The decline means the shares are down around 7% year to date and 22% from 12 months ago. The bank posted a weaker-than-expected first-half FY26 result in April and flagged tougher conditions for the remainder of the year. Investors reacted negatively, and analysts revised their outlooks following the announcement. Market Index data shows brokers have a sell rating on the shares. The average target price of $6.14 is just one cent above the current trading price at the time of writing.

Commonwealth Bank of Australia (ASX: CBA)

CBA shares are down around 0.5% on Tuesday afternoon, to $162.56 each. The shares are now around 1% higher year to date but nearly 8% lower than 12 months ago. The ASX 200 banking giant's shares dropped 14% in mid-May after it posted a disappointing third-quarter capital update. But after a sharp sell-off, investors quickly bought back into the stock. The banking giant seems to be supported by a flight to quality. In unstable markets, investors often rotate into large companies with stable dividends and dominant market positions to mitigate volatility. But it looks like brokers still see the ASX 200 bank shares as overpriced. They rate CBA shares as a strong sell and tip a 23% downside to an average target price of $124.20, at the time of writing. 

Beach Energy Ltd (ASX: BPT)

Beach Energy shares are slightly higher today, up around 0.2% to $1.10 at the time of writing. The oil and gas exploration and production company's shares are just over 6% lower year to date and 18% below their 12-month trading levels. Beach Energy posted its third-quarter update in April, which revealed softer sales, a guidance downgrade, and ongoing operational disruptions. The update spooked investors, and now many are worried about the company's earnings outlook from here. The majority of brokers have a sell rating on the shares, but the average $1.12 target price implies a small 2% upside at the time of writing.

The post Brokers rate these 5 ASX 200 shares as a sell! appeared first on The Motley Fool Australia.

As the calendars turn over to June, the S&P/ASX 200 Health Care Index (ASX: XHJ) sits almost 33% lower than at the start of the year. 

This makes it the worst performing sector in 2026 by some margin. 

ASX healthcare shares have been hit by a combination of earnings downgrades, rising cost pressures, weaker overseas earnings and investor concerns that growth across the sector is slowing. 

Because healthcare makes up a large part of the Australian market's growth-stock universe, higher interest rates and a strong rotation into energy, mining, and resource stocks have amplified the sell-off.

For investors, this could be an intriguing opportunity to gain exposure to quality companies at a historic discount. 

Here are three of the largest ASX healthcare stocks that are tipped to rebound from historic lows. 

Pro Medicus Ltd (ASX: PME)

Pro Medicus enjoyed a fast start to the month of June. 

The medical imaging technology company rose over 9% yesterday following a key contract win.

Investors will be hoping this is the start of a long-term rebound. 

Despite yesterday's 9% gain, it remains down 35% year to date. 

It closed yesterday at $144.46 per share. 

However brokers are confident it will rise significantly higher in the next 12 months. 

13 analysts offering a one year forecast have an average price target of $187.27 on Pro Medicus shares, indicating roughly 3% upside from current levels. 

11 of the 13 analysts rate the stock as a strong buy or buy. 

ResMed Inc (ASX: RMD)

While Pro Medicus shares started June off with a big rise, it was the opposite start to the month for ResMed shares. 

ResMed is a global leader in sleep technology.

Its share price fell more than 7% yesterday, and is now down 26% year to date. 

It now sits at a new 52-week low of $26.27. 

However this could now be a rare opportunity to scoop up this ASX healthcare stock at a significant value. 

Morgans expects a rebound over the next 12 months. The broker has a price target of $41.72 along with a buy rating. 

This indicates an upside potential of almost 59%. 

Sonic Healthcare Ltd (ASX: SHL)

It has been a similarly difficult 2026 for Sonic Healthcare shares. 

Its share price is down more than 14% year to date. 

However the global healthcare provider could also be set to recover in the near term. 

12 analysts forecasts via TradingView have an average one year price target of $23.40 on this ASX healthcare stock. 

This indicates an upside potential of 21% from current levels. 

The post Is June set to be the month of the ASX healthcare rebound? appeared first on The Motley Fool Australia.

Three ASX shares hitting new yearly lows were: 

• Brambles Ltd (ASX: BXB) crashed 20%
• Sonic Healthcare Ltd (ASX: SHL) dropped a further 2%
• Amcor Plc (ASX: AMC) fell 4%. 

For investors holding positions in these companies, it can be difficult not to panic when shares hit 52-week lows. 

For investors on the outside looking in, it can be an opportunity to find value in quality stocks. 

Let's see what experts are saying. 

Brambles crashes on trading update

Brambles is the world's largest supplier of reusable wooden pallets and crates used for storing and transporting goods. 

It operates in more than 60 countries, primarily under the Chep brand. The company touts itself as a pioneer of the 'sharing economy', managing a reusable pool of pallets and containers to service global supply chains and logistics.

Yesterday, it released a FY26 trading update.

It revealed revised FY26 guidance and the announcement of a new US$400 million share buy-back.

Brambles now expects sales revenue growth of 2% to 3% (previously 3% to 4%) and underlying profit growth of 3% to 5% (from 8% to 11%).

This news sent investors running for the hills, as the share price crashed 20% to a new 52-week low of $17.63. 

It may be a buy-low candidate after the crash.

The team at Jarden recently placed an overweight rating and $25.15 price target on Brambles shares. 

It's worth noting this was prior to the recent guidance downgrade. 

Sonic Healthcare continues its slump

Sonic Healthcare is a global healthcare provider. It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland.

It hit new 52-week lows yesterday closing at $18.39. 

Its share price is now down 18% year to date. 

It does have appeal as a dividend stock, as well as some capital upside. 

16 analyst forecasts via TradingView place an average price target of $24.25 on this ASX healthcare stock.

That indicates roughly 30% upside from current levels. 

Amcor continues to slide

Amcor operates as a holding company, which engages in the consumer packaging business.

It has struggled so far in 2026, falling 4% yesterday to take its year to date fall to roughly 18%. 

It recently released 3Q26 earnings which were largely in line with expectations. 

The team at Morgans is optimistic this ASX stock can bounce back from fresh 52-week lows. 

The broker recently lowered its price target to $65.40 (from $68.20), however maintained its buy recommendation. 

From yesterday's closing price of $51.44, this updated target indicates an upside potential of 27%. 

The post Should investors buy low on these ASX shares hitting 52-week lows? appeared first on The Motley Fool Australia.

While banks and infrastructure stocks often dominate the dividend conversation, there are other companies that can provide income from very different parts of the economy.

Here are three ASX dividend stocks that could be worth looking at.

Elders Ltd (ASX: ELD)

The first ASX dividend stock to look at is Elders.

It is one of Australia's leading agribusiness companies. It provides products and services to farmers across areas such as rural supplies, livestock, wool, real estate, and financial services.

This gives the company exposure to the agricultural economy without being tied to just one commodity. Its earnings can still be influenced by seasonal conditions and farmer confidence, but the breadth of the business provides several revenue streams.

This means that its dividends are linked to a business serving an essential industry. As demand for food and agricultural production continues over time, Elders remains positioned in a market with long-term relevance. This is particularly the case following the recent acquisition of Delta Agribusiness for $475 million, which boosts its position in crop protection and animal health.

Jumbo Interactive Ltd (ASX: JIN)

Another ASX dividend stock worth considering is Jumbo Interactive.

It operates digital lottery platforms and provides lottery software services. Its best-known brand is Oz Lotteries, which allows customers to buy lottery tickets online.

The company has a capital-light model, which can support strong cash generation when trading conditions are favourable. It also benefits from the continued shift from physical lottery purchases to digital channels.

Jumbo's earnings can be influenced by jackpot activity, as larger jackpots tend to drive higher customer engagement. But over the long term, the move toward online lottery participation remains an important growth driver.

With a digital platform, strong margins, and cash-generative operations, Jumbo offers a dividend profile that looks very different from traditional income stocks.

Sonic Healthcare Ltd (ASX: SHL)

A third ASX dividend stock that could help build passive income is Sonic Healthcare.

Sonic is a global pathology and laboratory medicine business. It provides diagnostic testing services across Australia, Europe, and North America.

Healthcare demand tends to be more resilient than many other parts of the economy. People still need medical testing through different economic conditions, which gives Sonic a defensive quality.

The company also has global scale, which helps diversify earnings across markets and healthcare systems.

While pandemic-related testing provided a temporary boost in past years, the underlying business remains supported by ageing populations, chronic disease management, and ongoing demand for diagnostics. This bodes well for its long-term dividend outlook.

The post 3 ASX dividend stocks to help build passive income appeared first on The Motley Fool Australia.

For income-focused investors, a pullback in market leaders like Sonic and JB Hi-Fi can present an opportunity. The ideal setup is a business that grows earnings over time while steadily lifting its dividend, especially when it's trading at a more attractive valuation.

Sonic Healthcare: global pathology leader

Sonic Healthcare is a global leader in pathology and diagnostic services, with operations spanning Australia, Europe, and the US. Its defensive earnings profile comes from essential healthcare services, which tend to hold up well across economic cycles.

One of its biggest drawcards is its dividend track record. The company has followed a progressive dividend policy, increasing its payout every year since 2013. In its FY26 half-year result, Sonic lifted its interim dividend by 2.3% to 45 cents per share.

The last two dividends declared totalled $1.08 per share, equating to a yield of about 5.4% excluding franking credits. If that level is maintained over the next year, it would translate into a grossed-up yield of roughly 7%, which is appealing for income investors.

There are risks to consider. Currency movements, regulatory changes, and fluctuations in testing volumes can influence Sonic's earnings, particularly following the post-pandemic normalisation in healthcare demand.

Broker sentiment on the ASX dividend stock is mixed. According to data from TradingView, the average price target sits at $24.49, implying potential upside of around 29% from current levels.

JB Hi-Fi: leading electronics seller

Turning to JB Hi-Fi, the retailer remains one of Australia's leading sellers of consumer electronics and home appliances. The ASX dividend stock has built a reputation for strong execution, cost control, and consistent profitability in a highly competitive sector.

JB Hi-Fi also has a solid dividend history. The company increased its dividend every year between 2013 and 2022, before a slight dip in 2023 amid higher interest rates and inflation pressures. Since then, it has resumed growing its payout.

In its FY26 half-year result, JB Hi-Fi lifted its dividend by 23.5% to $2.10 per share, supported by a 7.1% rise in earnings per share to $2.80. The ASX dividend share might not be able to repeat that pace of dividend growth in the near term. However, the income outlook remains attractive.

According to projections on CommSec, JB Hi-Fi is expected to deliver an annual dividend of around $3.41 in FY26. That equates to a potential grossed-up dividend yield of about 6% at current prices. Looking further ahead, CommSec forecasts that dividends will increase to $3.51 in FY27 and $3.83 in FY28, suggesting continued growth potential.

Risks include softer consumer spending, margin pressure, and the cyclical nature of retail demand, particularly in a high interest rate environment.

Even so, analysts remain constructive. Bell Potter Securities recently retained its buy rating on JB Hi-Fi with a $90.00 price target, suggesting a 22% upside. That's broadly in line with the average of 15 analyst forecasts.

Foolish Takeaway

The bottom line is that both Sonic Healthcare and JB Hi-Fi offer a combination of income and long-term growth potential.

With prices of both ASX dividend stocks under pressure in 2026, they may be worth considering for investors seeking reliable dividends at more attractive valuations.

The post 2 top ASX dividend stocks on sale, are they buys today? appeared first on The Motley Fool Australia.

Sonic Healthcare is a large global pathology business with operations across Germany, Australia, the USA, Switzerland, the UK, Belgium, Poland and New Zealand.

There are not many ASX shares that are as globally successful as Sonic Healthcare, and there's a lot to like about the business.

Excellent dividend credentials

The Sonic Healthcare board of directors has a progressive dividend policy, and the payout has increased every year since 2013. Indeed, the annual dividend has increased almost every year since the mid-1990s.

Very few businesses on the ASX have a long-term dividend record like that. Only Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) and APA Group (ASX: APA) have a similar sort of payout record.

In the FY26 half-year result, the ASX dividend share decided to increase its interim dividend by 2.3% to 45 cents per share.

The last two dividends declared came to $1.08 per share. Excluding franking credits, that equals a dividend yield of 5.4%. If it repeats that level of dividend over the next 12 months, it'd be a grossed-up dividend yield of 7%. I think any retiree would be happy with that level of passive income.

Earnings growth

Sonic Healthcare is not a business that's stuck with no growth – it's actively grown through both organic growth and acquisitions. The growing and ageing populations of its core markets give the business a promising tailwind of demand.

In the FY26 half-year result, the company reported revenue grew by 17% to $5.45 billion, with organic growth of 5%.

For me, earnings growth is the most important thing to drive the share price (and dividend) higher.

The ASX dividend share's HY26 operating profit (EBITDA) rose 10% to $907 million. Meanwhile, net profit increased 11% to $262 million and operating cash flow grew 10% to $682 million.

Given the company's focus on improving its operating leverage, acquisition synergy realisation, and ongoing cost control across the business, I think its earnings outlook is very positive.

According to the projection on Commsec, the business is forecast to generate earnings per share (EPS) of $1.18 in FY26. That means it's valued at 17x FY26's estimated earnings.

The company's EPS is expected to increase to $1.36 in FY27 and then $1.57 in FY28, suggesting there's a good chance of capital growth and dividend growth in the years ahead.

The post Why this ASX dividend share is a retiree's dream appeared first on The Motley Fool Australia.

This makes healthcare the worst performer of the 11 market sectors over the past 12 months.

It's even worse than technology, which is down 26% on fears that artificial intelligence (AI) is an existential threat to the sector.

However, while technology is turning around, healthcare remains in the doldrums.

The S&P/ASX 200 Health Care Index (ASX: XHJ) hit a six-year low of 25,193 points today.

What's going on?

Expert explains multiple headwinds hitting healthcare

Samy Sriram, a market analyst at online investment platform, Stake, says there are multiple reasons for healthcare's downward spiral.

First of all, there are currency headwinds and the likelihood of further interest rate rises in Australia.

Sriram said:

A weaker US dollar is eroding the offshore profits of giants like CSL Ltd (ASX: CSL), which accounts for 45% of the index.

At the same time, the RBA's decision to keep interest rates high to fight inflation is weighing heavily on the valuations of growth stocks like Pro Medicus Ltd (ASX: PME).

The Australian dollar is currently at a four-year high of 71.3 US cents, up 12% over 12 months.

Meanwhile, the Reserve Bank has already raised interest rates twice this year, and the market is pricing in a 76% chance of another hike next Tuesday.

Cost-of-living pressures force patients to compromise

Sriram also says cost-of-living pressures are impacting healthcare companies, not only in Australia, but also overseas.

She commented:

… persistent cost of living pressures in the US are alarmingly turning some medical procedures into optional expenses.

We've seen this with Cochlear Ltd (ASX: COH), an Australian company that manufactures and supplies hearing aids.

Their shares tumbled 35% due to patients deferring implants.

Last week, Cochlear downgraded its FY26 earnings guidance substantially.

The company now expects an FY26 underlying net profit of $290 million to $300 million, down from $435 million to $460 million.

Management commented:

Consumer sentiment has declined in key markets, reaching historic lows in the US.

The decline appears to be affecting discretionary healthcare decisions in the adults and seniors segment, adding to demand uncertainty in the near term.  

In Australia, consumer sentiment experienced its biggest fall in five years this month.

Iran war's impact on healthcare

The International Monetary Fund (IMF) has warned of a global recession as the fuel crisis drags on, with no end to the war in sight.

A recession would further erode consumer confidence due to inevitable job losses.

For now, Sriram said the war in Iran was hitting healthcare through higher shipping costs.

She commented:

With hospital operators like Ramsay Health Care Ltd (ASX: RHC) already being squeezed by rising staff wages and capped insurance payouts, geopolitical volatility is putting extra strain on the books, despite having a turnaround in 2026.

(Ramsay Health Care shares hit an 18-month high of $44.73 in March. The ASX 200 healthcare share is up 21% over six months.)

Cochlear also discussed shipping issues and capped insurance payouts last week.

Cochlear said it expects "order cancellations and a heightened risk of delivery delays to some countries" due to instability in the Middle East, and that lower reimbursements to patients in China "will lower premium tier sales in China in the second half".

FDA uncertainty under Trump

Biotech investors are also growing wary of the US Food and Drug Administration (FDA) under the Trump administration.

Leadership upheaval at the FDA, along with conflicting signals on approval standards across different categories of foods and medicines, has created uncertainty over how, and whether, new drugs and products will reach the market.

Earlier this month, a rare diseases advocacy group wrote to President Donald Trump and Health Secretary Robert F. Kennedy Jr., citing reduced flexibility at the FDA and a large proportion of biotech firms reporting difficulty raising funding.

Meanwhile, Secretary Kennedy has openly promoted vaccine scepticism and disputed scientific claims amid a global trend in fewer people seeking vaccinations, possibly as a reaction to mandatory programs and COVID-vaccine injuries during the pandemic.

At CSL's 2025 AGM, former CSL CEO Dr Paul McKenzie commented: "… we have seen a greater decline in influenza vaccination rates in the U.S. than we expected."

Last week, The Australian reported that the US military has now scrapped its annual flu shot requirement for service members.

Foolish Takeaway

All of these factors are hitting the healthcare sector hard, and sending many ASX 200 healthcare shares to multi-year low prices.

Here's how the top 10 ASX 200 healthcare shares by market capitalisation have performed over the past 12 months.

The post What's making healthcare the worst sector on the ASX 200, down 39% in a year? appeared first on The Motley Fool Australia.

But which ASX dividend shares could be in the buy zone right now? Let's look at three that analysts are tipping as buys:

Cedar Woods Properties Limited (ASX: CWP)

The first ASX dividend share that could be a buy is Cedar Woods.

It is one of Australia's leading property developers with a portfolio that is diversified by geography, price point, and product type. This includes subdivisions in emerging residential communities, high-density apartments, and townhouses in inner-city neighbourhoods.

Bell Potter believes the company is well-placed to benefit from Australia's chronic housing shortage.

It expects this to underpin fully franked dividends per share of 39 cents in FY 2026 and then 41 cents in FY 2027. Based on its current share price of $7.19, this would mean dividend yields of 5.4% and 5.7%, respectively.

The broker has a buy rating and $10.20 price target on its shares.

Premier Investments Ltd (ASX: PMV)

Another ASX dividend share that is being tipped as a buy is Premier Investments.

It owns brands such as Smiggle and Peter Alexander and holds a significant investment portfolio. Like many retailers, it has faced a tough consumer environment, which has dampened near-term earnings expectations.

But analysts at Macquarie remain positive, largely due to the strength of the Peter Alexander brand.

They are expecting the company to pay fully franked dividends of 95.2 cents per share in FY 2026 and then 97.4 cents per share in FY 2027. Based on its current share price of $12.53, this would mean generous dividend yields of 7.6% and 7.8%, respectively.

Macquarie has an outperform rating and $16.90 price target on its shares.

Sonic Healthcare Ltd (ASX: SHL)

A third ASX dividend share that is rated as a buy by analysts is Sonic Healthcare.

It is one of the world's leading healthcare providers with operations spanning laboratory medicine, pathology, radiology, and primary care medical services.

It has been going through a tough period, but analysts at Bell Potter believe the company is now positioned for sustainable growth.

This is expected to support partially franked dividends of $1.09 per share in FY 2026 and $1.11 per share in FY 2027. Based on its current share price of $19.93, this equates to dividend yields of 5.45% and 5.55%, respectively.

Bell Potter has a buy rating and $28.75 price target on its shares.

The post 3 ASX dividend shares to build a passive income appeared first on The Motley Fool Australia.

The best thing to do, in my view, is to look for businesses that grow their payouts over the long-term. In that sense, I think it's a good idea for an undervalued stock with a good dividend yield that can also deliver rising earnings.

That's why I'm particularly attracted to the ASX dividend stock Sonic Healthcare Ltd (ASX: SHL), which is down around 30% since August 2025.

Great credentials of an ASX dividend stock

One of the best things about the ASX healthcare share is that it has provided investors with regular dividend growth. Over the last 30 years, the business has increased its annual payout in most years, including every year of the last decade.

In the FY26 half-year result, Sonic increased its interim dividend per share by 2.3% to 45 cents. The company's board of directors has decided on a progressive dividend policy – the HY26 dividend was increased by 1 cent per share.

The last two dividends declared by the business equate to a dividend yield of 5.3%, or almost 7%, including franking credits, at the time of writing.

While the business isn't growing its dividend per share at a fast pace, it's being very consistent for shareholders.

Ongoing earnings growth

The business continues to deliver solid earnings growth. I'd say it's benefiting from growing and ageing populations in its core markets of Germany, Australia, the USA, Switzerland and the UK.

In the FY26 half-year result, it reported revenue growth of 17%, operating profit (EBITDA) growth of 10% to $907 million, net profit growth of 11% to $262 million and operating cash flow rose 10% to $682 million.

Within those numbers, the ASX dividend stock delivered organic revenue growth of 5%, which is a pleasing rate of expansion.

Sonic Healthcare reported in the HY26 result that operating leverage and synergies from acquisitions – demonstrated by EBITDA margin enhancement for the majority of the business. It also said that it has an ongoing focus on cost control.

The company noted that it's undertaking an operating review of US business, including "rationalisation of anatomical pathology operations". In other words, it's looking to grow profit by making some decisions with the US business.

Valuation

According to the projection on Commsec, the Sonic Healthcare share price is valued at 17x FY26's, which I think looks cheap given how defensive it is and the likelihood of further earnings growth.

The post 1 ASX dividend stock down 30% I'd buy right now appeared first on The Motley Fool Australia.

But which ones could be buys in April?

Let's look at three that analysts are currently recommending as buys to their clients. They are as follows:

Centuria Industrial REIT (ASX: CIP)

UBS thinks that Centuria Industrial REIT could be a top ASX dividend share to buy in April.

It is an industrial property company that owns a portfolio of high-quality industrial assets that is situated in urban infill locations throughout Australia and is underpinned by a quality and diverse tenant base.

UBS believes the company is positioned to pay dividends per share of 17 cents in FY 2026 and in FY 2027. Based on its current share price of $2.96, this would mean dividend yields of 5.75%.

The broker also sees 15% upside with its buy rating and $3.40 price target.

Sonic Healthcare Ltd (ASX: SHL)

Another ASX dividend share that could be a top buy in April is Sonic Healthcare.

It is a leading pathology and diagnostic imaging provider with operations across Australia, Europe, and the United States.

The team at Bell Potter is positive and thinks it could be a great option. This is based on its belief that the company's performance is about to improve meaningfully. The broker highlights that this is expected to be "driven by right sizing the business, the impact of acquisitions in FY24 and normalising organic operations post COVID."

With respect to dividends, Bell Potter is forecasting Sonic Healthcare to pay dividends per share of $1.09 in FY 2026 and then $1.11 in FY 2027. Based on its current share price of $20.53, this represents dividend yields of 5.3% and 5.4%, respectively.

Bell Potter has a buy rating and $28.75 price target on its shares, which implies potential upside of 40%.

Universal Store Holdings Ltd (ASX: UNI)

A third ASX dividend share that could be a top pick for income investors in April is Universal Store.

It is the youth fashion retailer behind the eponymous Universal Store brand, as well as Thrills and Perfect Stranger.

Morgans believes the company's positive form can continue and expects this to underpin further dividend increases.

It is forecasting fully franked dividends of 41 cents per share in FY 2026 and 46 cents per share in FY 2027. Based on its current share price of $7.32, this equates to dividend yields of 5.6% and 6.3%, respectively.

Morgans has a buy rating and $10.60 price target on its shares. This implies potential upside of 45% for investors.

The post 3 cheap ASX dividend shares offering 5% to 6% yields (and major upside) appeared first on The Motley Fool Australia.

ASX 200 shares soared 2.6% to an intraday peak of 8,804 points in morning trading on Tuesday.

Leading the market today are Guzman Y Gomez Ltd (ASX: GYG) shares, up 18%, and Nextdc Ltd (ASX: NXT), up 12%.

However, some ASX shares are bucking the trend.

Here are six stocks that hit 52-week lows today.

Sonic Healthcare Ltd (ASX: SHL)

Sonic Healthcare is one of several ASX healthcare shares trading at multi-year lows these days.

The sector faces multiple headwinds, including currency changes, US tariffs, and higher labour costs and other expenses.

The Sonic Healthcare share price fell to a decade-low of $18.88 today.

This ASX healthcare share has fallen 13% in the year to date (YTD) and 21% over the past year.

Ord Minnett has a hold rating on Sonic Healthcare with a 12-month share price target of $24.

Stockland Corp Ltd (ASX: SGP)

The Stockland share price fell to a 52-week low of $4.01 today.

Stockland shares are down 30% YTD.

In a separate article, my colleague Aaron has delved into the reasons this ASX property share has tanked in 2026.

Macquarie has just reiterated its buy rating on Stockland shares with a target price of $4.42.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price fell to a record low of $3.13 on Tuesday.

Endeavour shares have tumbled 14% YTD.

Citi recently downgraded this ASX consumer staples share to a hold rating.

The broker reduced its 12-month target from $4.30 to $3.70.

Atlas Arteria Group Ltd (ASX: ALX)

The Atlas Arteria share price fell to a nine-year low of $4.21 today.

Shares in the toll roads operator have fallen 13% YTD.

Last week, Morgan Stanley maintained its hold rating on Atlas Arteria shares.

The broker reduced its share price target from $5.06 to $4.96.

Lendlease Group (ASX: LLC)

The Lendlease share price dropped to an all-time low of $3.10 on Tuesday.

The ASX real estate share has fallen 39% in 2026.

Today, Macquarie reiterated its buy rating with a 12-month price target of $4.99.

Healius Ltd (ASX: HLS)

The Healius share price dropped to a record low of 51 cents today.

The ASX healthcare share has declined 43% YTD.

Goldman Sachs reiterated its sell rating on Healius shares last month.

The broker lowered its price target from 66 cents to 57 cents.

The post 6 ASX shares hitting 52-week lows amid today's market rally appeared first on The Motley Fool Australia.

Healthcare shares are facing many headwinds, as portfolio managers Joe Koh and Elan Miller from Blackwattle explain:

The sector as a whole has faced multiple headwinds, including currency and tariffs for the large multinationals and labour and cost pressures for the domestic players.

Today, eight of the 10 largest ASX 200 healthcare shares are trading at or close to multi-year or 52-week lows.

Does this present a buying opportunity?

Let's see what the experts say about three of these ASX 200 healthcare shares.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a decade-low of $19.57 last week.

This ASX 200 healthcare share has fallen 9.7% in the year to date (YTD) and 21.3% over the past year.

Last week, Ord Minnett issued a new note on Sonic Healthcare shares.

The broker maintained its hold rating with an unchanged target of $24.

Ord Minnett commented:

Ord Minnett finds it difficult to be constructive on Sonic given its inability to generate meaningful organic growth even after $3.3 billion of acquisitions over the past seven years.

There are undoubtedly some benefits from M&A, but other factors, such as price cuts and customer quotas specific to heathcare in its various markets, along with run-of-the mill costs such as wages and rents, appear to have constrained any meaningful earnings growth.

This view leads us to maintain our Hold recommendation despite the apparent value on offer.

Cochlear Ltd (ASX: COH)

The Cochlear share price tumbled to a six-year low of $160 last week.

This ASX 200 healthcare share has fallen 36.1% YTD and 36.4% over the past year.

Wilsons says Cochlear shares are trading at "a compelling entry point".

The broker commented:

Cochlear trades on a forward P/E multiple of ~26x, representing a >10 year low and a material discount to its 10-year average of ~42x.

We view this as a compelling entry point for a high-quality business ahead of accelerating earnings growth.

Wilsons expects the launch of Cochlear's Nucleus Nexa product to drive sales growth over the medium term.

Cochlear is approaching an inflection point in its earnings growth trajectory, supported by the ongoing global rollout of Nucleus Nexa (approved in mid-2025), which is its most significant product launch in over two decades.

Nexa's upgradeable firmware architecture represents a step-change in implant technology, enabling ongoing improvements in sound processing, connectivity and battery life via its Smart Sync app.

The rollout over the next few years should support ~10% CI unit growth over the medium term, with potential upside toward the mid-teens, while recurring implant upgrades will extend the Nexa's product cycle, supporting a longer duration of growth.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price crumbled to a two-year low of $107.75 late last month.

This ASX 200 healthcare share has fallen 49.3% YTD and 43.5% over the past year.

Pro Medicus shares are experiencing a period of correction after a ripsnorting two-year run through to mid 2025.

The Pro Medicus share price hit a record $336 per share in July last year.

Bell Potter has a buy rating and $240 price target on Pro Medicus shares.

The broker explains:

The company continues to announce new contract wins on a regular basis as the drivers of interest in its product offering remain firmly in place. The entire radiology industry is headed to cloud based (off premises) archiving. Put simply, the Visage 7 viewer, Workflow and Archive are the fastest and most advanced tools for the retrieval and viewing of large radiology files.

The platform is immensely scalable and relatively easily installed, providing it with a sustainable competitive advantage over the likes of peers Intelerad, Sectra, Philips and GE Healthcare. The company is conservatively managed and well owned by large institutional investors while the two founders continue to have a controlling stake.

The post 3 ASX 200 healthcare shares at multi-year lows appeared first on The Motley Fool Australia.

The ASX 200 stock is a leading healthcare provider with specialist operations in laboratory medicine, pathology, radiology, general practice medicine, and corporate medical services.

The company highlights that its diagnostic and clinical services are provided by more than 2,200 pathologists, radiologists, and other clinicians, and approximately 18,000 employees in science-based roles, including radiographers, sonographers, technicians and nurses.

Clearly, it is an impressive operation. But is this ASX 200 stock a buy? Let's see what Ord Minnett is saying about Sonic Healthcare.

What is Ord Minnett saying about this ASX 200 stock?

Unfortunately, the broker thinks that the company could be negatively impacted by proposed changes to medical fees in Germany. It said:

Ord Minnett has reviewed the medium-term outlook for Sonic Healthcare (SHL) given the increasing likelihood of reforms to Germany's Gebührenordnung für Ärzte (GOA), the medical fee schedule for patients with private health insurance that covers a wide range of consultation fees and outpatient services, including, in Sonic's case, laboratory fees.

These reforms pose a risk to Sonic given GOA reimbursements account for almost 1/3 of its German division's revenue, and equate to nearly 8% of group revenue, with drafts of the reforms aiming for a cut in laboratory fee reimbursements, on average, of 29% (although we expect this will be negotiated down as the legislation is developed and we model 20% in our numbers). The timing and details of mooted changes to the GOÄ are uncertain, although our talks with the industry indicate likely implementation from January 2028.

Should you buy, hold, or sell?

In light of this uncertainty and Sonic's lack of organic growth, the broker has put a hold rating and $24.00 price target on its shares.

However, this still implies potential upside of 18% for investors, which is better than what some buy recommendations offer.

Commenting on its recommendation, Ord Minnett said:

Post our review, we have made very minor changes to our near-term EPS forecasts and our target price remains at $24.00. Ord Minnett finds it difficult to be constructive on Sonic given its inability to generate meaningful organic growth even after $3.3 billion of acquisitions over the past seven years.

There are undoubtedly some benefits from M&A, but other factors, such as price cuts and customer quotas specific to healthcare in its various markets, along with run-of-the mill costs such as wages and rents, appear to have constrained any meaningful earnings growth. This view leads us to maintain our Hold recommendation despite the apparent value on offer.

The post Buy, hold, sell: What is Ord Minnett saying about this popular ASX 200 stock? appeared first on The Motley Fool Australia.

More than 400 companies in the ASX All Ords fell yesterday, with some hitting new 52-week lows.

Brokers say these ASX All Ords shares are good buys in today's market.

Here are their 12-month share price targets on each stock.

Objective Corporation Ltd (ASX: OCL)

The Objective Corporation share price fell to a 52-week low of $11.68 on Thursday.

The ASX All Ords tech share is down 29% in the year to date (YTD), and down 22% over the past 12 months.

Following the stock's recent fall, Morgans upgraded its rating from accumulate to buy.

However, the broker reduced its 12-month price target from $20 to $16.70.

Morgans said:

We see tailwinds remaining supportive of OCL's long-term growth momentum.

Generation Development Group Ltd (ASX: GDG)

The Generation Development Group share price fell to a 52-week low of $3.71 yesterday.

The ASX All Ords financial share is down 35% YTD, and down 21% over the past 12 months.

Morgans recently retained its buy rating but reduced its 12-month price target from $7.97 to $6.66.

The broker said:

We believe GDG has a great story, and management has executed well over time.

Jumbo Interactive Ltd (ASX: JIN)

The Jumbo Interactive share price dropped to a 52-week trough of $7.66 yesterday.

This ASX All Ords gaming share has fallen 32% YTD, and is down 25% over the past 12 months.

Jarden has a buy rating on Jumbo Interactive shares with a price target of $12.70.

Cleanaway Waste Management Ltd (ASX: CWY)

The Cleanaway Waste Management share price fell to a 52-week low of $2.31 on Thursday.

The ASX All Ords industrials share has fallen 11% YTD, and dropped 9% over 12 months.

Morgans has a buy rating with a 12-month price target of $3.11.

The broker commented:

1H26 was a mixed bag, with a minor bottom-of-the-range EBIT guidance upgrade.

Next catalyst is the investor strategy day planned for 21 April.

Earnings forecast adjustments are minimal, cashflow downgrades more material.

Sonic Healthcare Ltd (ASX: SHL)

The Sonic Healthcare share price fell to a 52-week low of $20.50 on Thursday.

The ASX All Ords healthcare share has deteriorated 8% YTD and 20% over the past year.

Macquarie has an outperform rating on Sonic Healthcare with a price target of $27.50.

Saluda Medical Inc (ASX: SLD)

Fellow ASX All Ords healthcare share, Saluda Medical, dropped to a 52-week low of 80 cents yesterday.

The Saluda Medical share price has tumbled 42% YTD, and is down 35% over 12 months.

Morgans has a speculative buy rating with a 12-month price target of $3.07.

The broker said:

1H26 showed solid revenue momentum, improving margins, and continued expansion of the US sales force, supporting confidence in a stronger 2H.

Reiteration of FY26 revenue guidance (US$85m) added further comfort and now expects to exceed IPO metrics for gross margin, adjusted EBITDA and cash burn.

The post 6 ASX All Ords shares at 52-week lows: Experts say buy appeared first on The Motley Fool Australia.

When I look for ASX dividend stocks, I tend to focus on businesses that combine reliable income with solid underlying operations. A dividend is great, but it is even better when it is supported by a strong business model and the potential for earnings to grow over time.

With that in mind, here are three dividend-focused ASX stocks I would be looking at this month.

Commonwealth Bank of Australia (ASX: CBA)

I think it is impossible to talk about dividend investing on the ASX without mentioning Commonwealth Bank of Australia.

The bank has built a reputation as the highest-quality lender in Australia thanks to its dominant deposit base, strong technology platform, and disciplined approach to lending.

CBA's dividend yield may not look spectacular at first glance because the share price has rallied strongly over the past few years. However, it still provides a healthy income stream.

Consensus estimates currently point to a fully franked dividend of about $5.20 per share in FY2026. Based on the current CBA share price of $171.09, that implies a yield of a little over 3%, before taking franking credits into account.

For income investors, those franking credits make a meaningful difference. They can significantly boost the effective yield on an after-tax basis.

What I like most about CBA is the consistency. Banks will always face economic cycles, but CBA has shown time and again that it can generate strong profits and maintain dividends through changing conditions.

Sonic Healthcare Ltd (ASX: SHL)

Another ASX dividend stock that stands out to me is Sonic Healthcare.

Sonic operates one of the world's largest medical diagnostics businesses, with laboratories and pathology services across Australia, Europe, and the United States.

Healthcare demand tends to be relatively stable, which helps make Sonic's earnings more predictable than many other industries. That stability can translate into reliable dividends over time.

Consensus forecasts currently suggest Sonic could pay partially franked dividends of around $1.10 per share this financial year. With its shares trading at about $21.28, that equates to a dividend yield of just over 5%.

In my view, the combination of defensive healthcare demand and a solid dividend yield makes Sonic an appealing option for income-focused investors.

Harvey Norman Holdings Ltd (ASX: HVN)

The third ASX dividend stock on my list is Harvey Norman.

Retail businesses can sometimes produce strong dividends when they are run conservatively and generate healthy cash flow. I think Harvey Norman is a good example of that.

The company's unique franchise model allows it to earn income from both retail operations and property ownership. That property exposure has historically provided a strong asset backing for the business.

Consensus estimates predict Harvey Norman will pay around 31 cents per share in fully franked dividends this year. With the share price currently around $5.24, that represents a dividend yield of roughly 6%.

For investors seeking higher income, that yield could be particularly appealing.

Foolish takeaway

Dividend investing isn't just about chasing the highest yield. In my experience, the best income stocks are usually backed by strong businesses that can keep generating cash flow year after year.

Commonwealth Bank, Sonic Healthcare, and Harvey Norman each offer a combination of income potential and established business models. For that reason, they are three ASX stocks I think are worth considering.

The post My 3 best ASX dividend-focused stocks to buy in March appeared first on The Motley Fool Australia.

But for long-term investors, pullbacks can also create opportunities to lock in attractive dividend yields.

These ASX dividend shares offer a combination of income potential and established businesses.

Sonic Healthcare

This ASX dividend share is one of the world's largest medical diagnostics providers, operating laboratories and pathology services across Australia, Europe, and North America. The company's scale and global footprint are major strengths.  

Another positive is the long-term demand outlook. Healthcare testing and diagnostics are essential services, and aging populations across developed markets should support steady demand for Sonic's services over time.

However, there are risks investors should keep in mind. Healthcare shares are exposed to government funding changes and regulatory shifts, which can affect margins. Rising wages in the healthcare sector are also a challenge for pathology operators.

Macquarie has recently assigned the ASX dividend share an outperform rating with a $27.50 price target. This points to a 25% upside over 12 months.

For income investors, the broker expects the company to pay partially franked dividends of 104 cents per share in FY2026 and 100 cents per share in FY2027.

At the current share price of $21.97, this equates to dividend yields of approximately 4.7% for FY2026 and 4.55% for FY2027.

Super Retail Group

The ASX dividend share is the retailer behind well-known brands including Supercheap Auto, Rebel, BCF, and Macpac.

A key strength of the business is its brand diversification. By operating across multiple retail categories, Super Retail reduces reliance on any single segment of consumer spending. The group also generates strong operating cash flow, which supports dividends and store expansion.

The main risk for the ASX dividend share is its exposure to consumer spending cycles. If economic conditions weaken or household budgets tighten, sales across discretionary retail categories can fall. Retail competition and promotional activity can also weigh on margins.

Even so, this ASX dividend share is known for generous shareholder returns. The company currently pays about 96 cents per share annually in dividends, offering a yield of roughly 6.5%, with payments typically made twice a year.

Most analysts rate the dividend stock a buy. They have set the average 12-month price target at $16.66, implying a 13% upside. This could bring the year's total earnings to 19.5%.

Harvey Norman Holdings

Harvey Norman is one of Australia's most recognisable retailers, selling electronics, furniture, bedding, and appliances through a large franchise network. One of the company's biggest strengths is its property portfolio, as many stores sit on land owned by the group.

This property ownership helps underpin the balance sheet and can provide an additional source of value beyond the retail operations. Harvey Norman also generates strong cash flow from its franchise model, which supports shareholder distributions.

However, the ASX dividend share is still exposed to the consumer cycle. Sales of big-ticket household goods can slow when interest rates are high or when housing markets weaken. Competition from online retailers is another ongoing challenge.

Macquarie remains positive on the ASX dividend share. It believes the company is positioned to pay fully-franked dividends per share of 27.8 cents in FY 2026 and 31.2 cents in FY 2027. Based on its current share price of $5.46, this represents dividend yields of 5.1% and 5.7%, respectively.

The broker has a buy rating and $6.60 price target on the retail stock. This points to a 23% upside at current price levels.

The post 3 ASX dividend shares to buy today with $5,000 appeared first on The Motley Fool Australia.

They have recently been recommended as buys by brokers in March. Here's why they could be top picks for income investors with $3,000 to put to work in the share market:

Cedar Woods Properties Limited (ASX: CWP)

Bell Potter thinks Cedar Woods could be an ASX dividend stock to buy this month.

It is one of Australia's leading property companies, owning a high-quality portfolio that is diversified by geography, price point, and product type. The broker believes that this leaves it well-positioned to be a big winner from Australia's chronic housing shortage.

Bell Potter expects this to support dividends per share of 39 cents in FY 2026 and then 41 cents in FY 2027. Based on its current share price of $8.73, this equates to 4.5% and 4.7% dividend yields, respectively.

The broker has a buy rating and $10.20 price target on its shares.

Premier Investments Ltd (ASX: PMV)

Another ASX dividend stock to consider for income is Premier Investments.

It is the owner of popular retail brands Smiggle and Peter Alexander, as well as a sizeable stake in appliance manufacturer Breville Group Ltd (ASX: BRG). These assets are consistently generating strong free cash flow, which is usually returned to shareholders in the form of dividends.

Macquarie is positive on this one, especially given its belief that the Peter Alexander brand is being significantly undervalued.

As for income, it expects fully franked dividends of 79 cents per share in FY 2026 and then 90.3 cents per share in FY 2027. Based on its current share price of $12.87, this equates to dividend yields of 6.1% and 7%, respectively.

The broker currently has an outperform rating and $16.20 price target on the shares.

Sonic Healthcare Ltd (ASX: SHL)

A final ASX dividend stock to consider according to analysts is Sonic Healthcare.

It is a global medical diagnostics company, operating laboratories and collection centres across Australia, Europe, and the United States. Its services are tied to healthcare demand rather than economic cycles, which can provide a degree of earnings resilience.

Macquarie is also positive on this one and is recommending Sonic Healthcare to clients.

The broker recently put an outperform rating and $27.50 price target on its shares.

In terms of income, Macquarie is forecasting partially franked dividends of 104 cents per share in FY 2026 and 100 cents per share in FY 2027. Based on the current share price of $23.01, this implies dividend yields of 4.5% and 4.35%, respectively.

The post 3 ASX dividend stocks to buy with $3,000 in March appeared first on The Motley Fool Australia.

Will the market be able to bounce back from this on Wednesday? Here are five things to watch:

ASX 200 to fall

The Australian share market looks set to fall again on Wednesday after a poor night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 104 points or 1.1% lower. In late trade in the United States, the Dow Jones is down 0.5%, the S&P 500 is down 0.75% and the Nasdaq is 0.9% lower. The Dow Jones was down 2% at one stage before recovering.

Oil prices jump again

ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a good session on Wednesday after oil prices stormed higher overnight. According to Bloomberg, the WTI crude oil price is up 5% to US$74.79 a barrel and the Brent crude oil price is up 5% to US$81.63 a barrel. This was driven by threats by Iran to close the Strait of Hormuz.

ASX 200 shares going ex-div

Another group of ASX 200 shares are going ex-dividend today and could trade lower. This includes Chemist Warehouse owner Sigma Healthcare Ltd (ASX: SIG), healthcare company Sonic Healthcare Ltd (ASX: SHL), and supermarket giant Woolworths Group Ltd (ASX: WOW). The latter will be paying a fully franked 45 cents per share dividend next month on 2 April.

Gold price tumbles

ASX 200 gold shares Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a difficult session on Wednesday after the gold price sank overnight. According to CNBC, the gold futures price is down 3.6% to US$5,121 an ounce. A strong US dollar and higher rate bets put pressure on the precious metal.

Buy Life360 shares

Life360 Inc. (ASX: 360) shares are undervalued according to analysts at Bell Potter. This morning, in response to its FY 2025 results, the broker has retained its buy rating on the family safety technology company's shares with a trimmed price target of $40.00. It said: "2025 revenue of US$489m was slightly above our forecast of US$488m and VA consensus of US$486m and was top end of the US$486-489m guidance range. Adjusted EBITDA of $93m, however, was a beat versus our forecast of US$90m and VA consensus of US$88m and was also above the US$87-92m guidance range. Cash at year end was US$495m which was ahead of our forecast of US$476m."

The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.

In order to receive a dividend, you must own the ASX share before its ex-dividend date.

Here is a sample of the large number of ASX All Ords shares with ex-dividend dates next week.

ASX All Ords shares about to go ex-dividend

Which companies will we hear from today?

The big one today is the half-yearly report from supermarket network Coles Group Ltd (ASX: COL).

Woolworths shares ripped this week after the ASX All Ords consumer staples giant reported a 16% profit lift to $859 million for 1H FY26.

We'll also hear from TPG Telecom Ltd (ASX: TPG), Michael Hill International Ltd (ASX: MHJ), and Pexa Group Ltd (ASX: PXA).

The latest report from The Star Entertainment Group Ltd (ASX: SGR) will also be interesting, as investors seek further news on the turnaround plan for the beleaguered casino operator.

Yesterday, Star Entertainment shares bounced on news of a debt refinancing deal, including extra liquidity to fund the turnaround plan.

The post 35 ASX All Ords shares with ex-dividend dates next week appeared first on The Motley Fool Australia.